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■ CLINICAL COMMENTARY
Encourage varicella vaccination, 
except for the immunocompromised
For many parents, vaccination decisions are
made based on school district requirements.
Varicella zoster vaccine is an exception to that
rule. Parents can choose to immunize their
child at 12 months or wait and let nature take
its course—hopefully before the child starts
kindergarten. The major concern with the vac-
cine has been its long-term efficacy. Although
no one knows for sure how long immunity is
sustained, studies show that detectable anti-
bodies are present for up to 20 years. 
As a parent and physician, my decision to
vaccinate my daughter was made after I wit-
nessed an 8-year-old boy in the emergency
room with respiratory distress secondary to
complications from chickenpox. This experi-
ence reinforced for me that chickenpox is a life-
threatening disease. The effects of chickenpox
include scarring as well as time away from
work for parents. I therefore encourage vari-
cella vaccination for my patients, with the only
exception being those who are immunocompro-
mised, for whom we have no data. 
To the question of whether we should we vac-
cinate children to prevent chickenpox, I give a
resounding “yes.”
Kristen Rundell, MD, University of Colorado Health
Sciences Center, Denver
Do antibiotics prevent
recurrent UTI in children 
with anatomic abnormalities?
■ EVIDENCE-BASED ANSWER
Evidence is insufficient to recommend for or
against antibiotic prophylaxis to prevent recur-
rent urinary tract infections (UTI) in children with
anatomic abnormalities. Guidelines acknowledge
this lack of evidence, but still recommend using
prophylactic antibiotics in children with vesicu-
loureteral reflux (strength of recommendation: B,
based on poor-quality or inconclusive cohort and
randomized controlled studies).1–3 No controlled,
prospective studies have examined the effective-
ness of prophylactic antibiotics to prevent UTI
recurrence or renal scarring. 
■ EVIDENCE SUMMARY
Recommendations about antibiotic prophylaxis
are based on several premises. Reflux predispos-
es children to acute pyelonephritis; reflux plus
infection leads to reflux nephropathy and ulti-
mately to renal scarring. In theory, if antibiotics
could be initiated at the appropriate time and be
maintained until reflux resolves, we could suc-
cessfully prevent infection and scarring.4
A recent systematic review evaluated the use
of antibiotics to prevent UTI in children.5 This
review of 5 randomized controlled trials included
a total of 463 children between the ages of 2
months to 16 years. Three out of 5 trials evaluat-
ed the effectiveness of antibiotic treatment for 2
to 6 months to prevent subsequent off-treatment
recurrence. The 2 smaller trials (n=71) evaluated
the use of low-dose long-term antibiotics to pre-
vent UTI. 
There was a clinically, but not statistically,
significant trend towards reduced risk of UTI
during long-term antibiotic treatment (risk
reduction [RR]=0.31; 95% confidence interval
[CI]=0.10–1.00); however, no sustained benefit
was seen once antibiotics were stopped
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although a clinically important effect has not been
excluded, the regular use of antimicrobial prophy-
laxis for most patients who have neurogenic 
bladder caused by spinal cord dysfunction is not
supported at this time.8
Poor compliance may be an issue with long-
term prophylaxis and may represent patient or
parent practice.
9
One study found that in children
taking low-dose trimethoprim, 97% of the parents
reported giving antibiotics on daily basis, but in
31% of subjects, trimethoprim was not detectable
in the urine.6 Risk of prophylaxis includes nausea,
vomiting, and rash in 8% to 10% of patients; devel-
opment of resistant organisms; and change in
indigenous microflora.6 One study of resistance
found that children who received antibiotics for
more than 4 weeks in the previous 6 months were
more likely to have resistant Escherichia coli
isolates than children who had not received pro-
longed antibiotic treatment (odds ratio [OR]=13.9;
95% CI, 8.2–23.5). Children with abnormalities 
of the genitourinary tract were approximately 
4 times more likely to have resistant isolates of 
E coli than children without abnormalities of the
genitourinary tract (OR=3.9; 95% CI, 2.7–5.7).11
■ RECOMMENDATIONS FROM OTHERS
The American Academy of Pediatrics, American
Urological Association, and the Swedish Medical
Research Council guidelines recommend prophy-
laxis for children with reflux (Table), but they all
acknowledge that the recommendations are not
supported by well-designed randomized con-
trolled trials.1–3 No guidelines are available for
children with neurogenic bladder and recurrent
urinary tract infections.7
Amer Shakil, MD, Lane Reed, MD, Department of
Family Practice and Community Medicine, University of Texas
Southwestern, Dallas; Laura Wilder, MLS, University of
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(RR=0.79; 95% CI, 0.61–1.02). There were
many problems with the methodological quality
of these trials, including significant heterogene-
ity. The researchers concluded that well-
designed randomized controlled trails are still
needed to evaluate this commonly used inter-
vention in the pediatric population.4 Benefits 
for long-term prophylaxis are even less clear 
in children with low-grade reflux (I–II).5
Furthermore, no randomized controlled trials
assess whether prophylaxis prevents the devel-
opment of new renal scars in children.6
In addition, a recent systematic review of stud-
ies done in children with normal urinary tracts, as
well in children with neurogenic bladders, found
that the available evidence is of low quality. Only
6 out of 31 potential studies fulfilled the inclusion
criteria. These were small (mean sample size was
28), and the quality scores of all 6 trials were low,
indicating that the evidence may be unreliable.7
Two of 3 studies done in children with normal
urinary tracts demonstrated statistically signifi-
cant higher rates of UTI recurrence in control
groups compared with treatment groups receiv-
ing 6 to 10 months of either nitrofurantoin or cot-
rimoxazole (RR=24–31). The third study showed
no difference between groups. 
One of 2 trials in children with neurogenic blad-
der demonstrated higher recurrence rates of 2.9
per 10 patient years for patients receiving antibi-
otics compared with 1.5 in the untreated group.
The other study showed lower recurrence rates of
17.1 for patients receiving antibiotics, compared
with 33 in the untreated group.7 Neither of these
findings were statistically significant. 
A different meta-analysis of 15 controlled clin-
ical trials in children with neurogenic bladder due
to spinal cord dysfunction. This analysis showed
that antibiotic prophylaxis was associated with a
reduction in asymptomatic bacteruria among chil-
dren with acute spinal cord injury (P<.05), but
there was no significant reduction in sympto-
matic infections. Prophylaxis resulted in an
approximately twofold increase in antimicrobial-
resistant bacteria. The researchers concluded that
No controlled prospective studies
examine the effectiveness 
of antibiotics to prevent UTI
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■ CLINICAL COMMENTARY:
UTI prevention most successful when
the child exhibits efficiency of voiding
The relative benefit of antibiotic prophylaxis in
prevention of UTI in children with anatomic
abnormalities like vesicoureteral reflux could
best be determined if all other risk factors for
UTI were controlled. Unfortunately, these other
factors are often more significant in promoting
UTI than is reflux, and they are also more diffi-
cult to quantify. Voiding dysfunction and con-
stipation can both increase bladder storage
pressures and postvoid residual urine volumes,
and as such greatly predispose children for
UTI. Furthermore, a distended colon provides
an abundant reservoir of pathogens with an
array of uropathogenic virulence factors.
Published reports have failed to detect signif-
icant benefit for antibiotic prophylaxis in part
because the children studied possess varying
risks for UTI. Prevention of UTI is most suc-
cessful when the child exhibits efficiency of
voiding and elimination. Clinical practice in
pediatric urology advocates use of antibiotic
prophylaxis in children with vesicoureteral
reflux. Reflux should be suspected in children
with hydroureter, multicystic renal dysplasia,
ureteral duplication, and ureterocele.
William R. Strand, MD, Division of Pediatric Urology,
University of Texas Southwestern Medical Center, Dallas
Oral antibiotics for prophylaxis of urinary tract infections in children 
Antimicrobial Prophylaxis dosage
Trimethoprim/sulfamethoxazole 2 mg of TMP, 10 mg of SMX per kg as single bedtime or
(TMP/SMX) (Bactrim, Septra) 5 mg of TMP, 25 mg of SMX per kg twice per week
Nitrofurantoin (Macrodantin) 1–2 mg/kg as single daily dose
Cephalexin (Keflex) 10 mg/kg as single daily dose
Amoxicillin 10 mg/kg as single daily dose
Sulfisoxazole (Gantrisin Pedatric) 10–20 mg/kg divided every 12 h
Modified with permission from AAP 1999;3 Allen et al1999.10
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